Phase 1b Study of Dulanermin (recombinant human Apo2L/TRAIL) in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Patients With Advanced Non-Squamous Non-Small-Cell Lung Cancer

J.C. Soria, E.F. Smit, D. Khayat, B. Besse, X.Q. Yang, C.P. Hsu, D. Reese, J. Wiezorek, F. Blackhall

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)1527-1533
JournalJournal of Clinical Oncology
Issue number9
Publication statusPublished - 2010

Cite this